Antibody-Based Therapeutics in Small Cell Lung Cancer: A Narrative Review
Andrea Torchia,1,2,* Giuliana Ciappina,3,* Maristella Giammaruco,2 Ilaria Monteferrante,4 Lorenza Landi,5 Federico Cappuzzo2 1Clinical and Molecular Medicine, Sapienza - Università di Roma, Rome, Italy; 2Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy; 3...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-04-01
|
| Series: | Biologics: Targets & Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/antibody-based-therapeutics-in-small-cell-lung-cancer-a-narrative-revi-peer-reviewed-fulltext-article-BTT |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850198852593778688 |
|---|---|
| author | Torchia A Ciappina G Giammaruco M Monteferrante I Landi L Cappuzzo F |
| author_facet | Torchia A Ciappina G Giammaruco M Monteferrante I Landi L Cappuzzo F |
| author_sort | Torchia A |
| collection | DOAJ |
| description | Andrea Torchia,1,2,* Giuliana Ciappina,3,* Maristella Giammaruco,2 Ilaria Monteferrante,4 Lorenza Landi,5 Federico Cappuzzo2 1Clinical and Molecular Medicine, Sapienza - Università di Roma, Rome, Italy; 2Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy; 3Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy; 4Department of Anesthesiology, Intensive Care and Pain Therapy, IRCCS Regina Elena National Cancer Institute, Rome, Italy; 5Clinical Trials Unit: Phase 1 and Precision Medicine, IRCCS Regina Elena National Cancer Institute, Rome, Italy*These authors contributed equally to this workCorrespondence: Federico Cappuzzo, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, Rome, 00144, Italy, Email f.cappuzzo@gmail.com, federico.cappuzzo@ifo.itAbstract: Small-cell lung cancer (SCLC) is the most aggressive lung cancer, mostly diagnosed at advanced stage, and with few therapeutic options for patients failing the first-line treatment. Antibody-based therapies, such as antibody-drug conjugates and T-cell engagers, are emerging as a promising option in the treatment of various solid tumors, including SCLC. T-cell engagers are molecules able to trigger the T-cell-mediated tumor cell death binding, at the same time, a T-cell and a tumor cell target. Tarlatamab is a DLL3-directed bi-specific T-cell engager (BiTE) whose efficacy was evaluated in a Phase 2 study. Antibody-drug conjugates (ADC) consist of a tumor-directed monoclonal antibody conjugated to a cytotoxic payload able to selectively kill tumor cells through different mechanisms. Ifinatamab-deruxtecan is an anti-B7-H3 ADC showing efficacy in pretreated SCLC patients in a phase 2 clinical trial. Sacituzumab govitecan is a Trop-2-directed ADC already used in other tumor types and evaluated in SCLC in the phase 2 TROPiCS-03 trial, with positive results. Bispecific antibodies targeting VEGF and PD-(L)1 showed antitumor activity in phase 1 and 2 clinical trials. Other antibody-based agents are currently at an earlier phase of their clinical development and showed a promising activity. Novel antibody-based agents could potentially acquire a prominent role in the treatment of SCLC, a field with few therapeutic options. Direct comparisons with the current standard of care still lack, however Phase 3 trials are currently ongoing.Keywords: small-cell lung cancer, treatment, antibody, antibody–drug conjugate, T-cell engager, bispecific antibody |
| format | Article |
| id | doaj-art-3e7ece5b76e74bbb936eb241344fb948 |
| institution | OA Journals |
| issn | 1177-5491 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Biologics: Targets & Therapy |
| spelling | doaj-art-3e7ece5b76e74bbb936eb241344fb9482025-08-20T02:12:46ZengDove Medical PressBiologics: Targets & Therapy1177-54912025-04-01Volume 19189199102126Antibody-Based Therapeutics in Small Cell Lung Cancer: A Narrative ReviewTorchia ACiappina GGiammaruco MMonteferrante ILandi LCappuzzo FAndrea Torchia,1,2,* Giuliana Ciappina,3,* Maristella Giammaruco,2 Ilaria Monteferrante,4 Lorenza Landi,5 Federico Cappuzzo2 1Clinical and Molecular Medicine, Sapienza - Università di Roma, Rome, Italy; 2Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy; 3Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy; 4Department of Anesthesiology, Intensive Care and Pain Therapy, IRCCS Regina Elena National Cancer Institute, Rome, Italy; 5Clinical Trials Unit: Phase 1 and Precision Medicine, IRCCS Regina Elena National Cancer Institute, Rome, Italy*These authors contributed equally to this workCorrespondence: Federico Cappuzzo, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, Rome, 00144, Italy, Email f.cappuzzo@gmail.com, federico.cappuzzo@ifo.itAbstract: Small-cell lung cancer (SCLC) is the most aggressive lung cancer, mostly diagnosed at advanced stage, and with few therapeutic options for patients failing the first-line treatment. Antibody-based therapies, such as antibody-drug conjugates and T-cell engagers, are emerging as a promising option in the treatment of various solid tumors, including SCLC. T-cell engagers are molecules able to trigger the T-cell-mediated tumor cell death binding, at the same time, a T-cell and a tumor cell target. Tarlatamab is a DLL3-directed bi-specific T-cell engager (BiTE) whose efficacy was evaluated in a Phase 2 study. Antibody-drug conjugates (ADC) consist of a tumor-directed monoclonal antibody conjugated to a cytotoxic payload able to selectively kill tumor cells through different mechanisms. Ifinatamab-deruxtecan is an anti-B7-H3 ADC showing efficacy in pretreated SCLC patients in a phase 2 clinical trial. Sacituzumab govitecan is a Trop-2-directed ADC already used in other tumor types and evaluated in SCLC in the phase 2 TROPiCS-03 trial, with positive results. Bispecific antibodies targeting VEGF and PD-(L)1 showed antitumor activity in phase 1 and 2 clinical trials. Other antibody-based agents are currently at an earlier phase of their clinical development and showed a promising activity. Novel antibody-based agents could potentially acquire a prominent role in the treatment of SCLC, a field with few therapeutic options. Direct comparisons with the current standard of care still lack, however Phase 3 trials are currently ongoing.Keywords: small-cell lung cancer, treatment, antibody, antibody–drug conjugate, T-cell engager, bispecific antibodyhttps://www.dovepress.com/antibody-based-therapeutics-in-small-cell-lung-cancer-a-narrative-revi-peer-reviewed-fulltext-article-BTTsmall-cell lung cancertreatmentantibodyantibody-drug conjugatet-cell engagerbispecific antibody |
| spellingShingle | Torchia A Ciappina G Giammaruco M Monteferrante I Landi L Cappuzzo F Antibody-Based Therapeutics in Small Cell Lung Cancer: A Narrative Review Biologics: Targets & Therapy small-cell lung cancer treatment antibody antibody-drug conjugate t-cell engager bispecific antibody |
| title | Antibody-Based Therapeutics in Small Cell Lung Cancer: A Narrative Review |
| title_full | Antibody-Based Therapeutics in Small Cell Lung Cancer: A Narrative Review |
| title_fullStr | Antibody-Based Therapeutics in Small Cell Lung Cancer: A Narrative Review |
| title_full_unstemmed | Antibody-Based Therapeutics in Small Cell Lung Cancer: A Narrative Review |
| title_short | Antibody-Based Therapeutics in Small Cell Lung Cancer: A Narrative Review |
| title_sort | antibody based therapeutics in small cell lung cancer a narrative review |
| topic | small-cell lung cancer treatment antibody antibody-drug conjugate t-cell engager bispecific antibody |
| url | https://www.dovepress.com/antibody-based-therapeutics-in-small-cell-lung-cancer-a-narrative-revi-peer-reviewed-fulltext-article-BTT |
| work_keys_str_mv | AT torchiaa antibodybasedtherapeuticsinsmallcelllungcanceranarrativereview AT ciappinag antibodybasedtherapeuticsinsmallcelllungcanceranarrativereview AT giammarucom antibodybasedtherapeuticsinsmallcelllungcanceranarrativereview AT monteferrantei antibodybasedtherapeuticsinsmallcelllungcanceranarrativereview AT landil antibodybasedtherapeuticsinsmallcelllungcanceranarrativereview AT cappuzzof antibodybasedtherapeuticsinsmallcelllungcanceranarrativereview |